Indoco Remedies Ltd, which has carved a place for itself in the international arena and is exporting a number of generic products in the regulated and emerging markets, is poised to scale higher peaks.
Headquartered in Mumbai, the US$ 149 million Indoco Remedies is a fully integrated, research-oriented Indian pharma company having presence in 55 countries, employing over 5500 people including over 300 skilled scientists.
The company has nine manufacturing facilities, out of which six are for finished dosages and three for APIs and supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, SUKL-Czech Republic, Cofepris – Mexico, TGA-Australia, JAZMP- Slovenia, MCC-South Africa, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya and FDB-Ghana.
The company recently acquired a Oral Solid Dosage (OSD) manufacturing facility located at Baddi of Micro Labs Ltd., Bangalore. The facility is spread over an area of 18,000 sqm, out of which 11,000 is the built-up area. It produces 4.3 billion tablets and 50 million capsules p.a.
Indoco develops, manufactures and distributes a wide range of pharmaceutical products for the Indian and international markets. It generates more than 67 million prescriptions annually from over 2,10,000 doctors in India. Indoco’s 10 domestic marketing divisions cater to different therapeutic segments including Respiratory, Anti-Infectives, Dental Care, Pain Management, Gastroenterology, Opthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, ATM, Oxipod, Cital, Sensoform, Cloben-G, Sensodent – KF, Karvol Plus, Glychek, Vepan, Tuspel Plus, Flamar etc.
The company products are distributed in over 55 countries across the globe, including USA and EU. Its branded formulations are promoted in emerging markets of South East Asia, Africa, Latin America and CIS countries. The company participates in various tenders floated by authorities from different countries. The company has major tie-ups with big generic companies and works in close co-ordination with its customers for leveraging core competencies.
AnaCipher, Indoco’s Analytical Service Division has been carved to serve customers for their analytical research needs, utilizing the state-of-the-art instruments/infrastructure and highly experienced human resources. XIDEL offers end –to-end engineering and consulting services to all phases of project development, right from project design to validation. XIDEL has been providing these services to the pharmaceuticals & API sector for the past 15 years and has completed several projects which are now award winning & internationally approved facilities that produce high quality products efficiently and economically.
AnaCipher CRO, based in Hyderabad, is a GDUFA (USFDA) registered clinical research facility and is spread over 30,000 sq. ft area and staffed by experienced professionals providing clinical trial solutions, including bioavailability and bioequivalence (BA/BE)/Phase I/Phase II studies for pharmaceutical companies globally.